EIF2AK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL868551	1.00	20/20
SCHEMBL869013	1.00	20/20
SCHEMBL868471	0.80	20/20
SCHEMBL868186	0.76	20/20
SCHEMBL868270	0.76	20/20
SCHEMBL869403	0.75	20/20
SCHEMBL868766	0.74	20/20
SCHEMBL868009	1.00	19/20
SCHEMBL868634	1.00	19/20
SCHEMBL868637	1.00	19/20
SCHEMBL868836	1.00	19/20
SCHEMBL868900	1.00	19/20
SCHEMBL868966	1.00	19/20
SCHEMBL869043	1.00	19/20
SCHEMBL869278	1.00	19/20
SCHEMBL869470	1.00	19/20
SCHEMBL869248	0.88	19/20
SCHEMBL869173	0.88	19/20
SCHEMBL868476	0.87	19/20
SCHEMBL867653	0.87	19/20

Clinical trials — most relevant to EIF2AK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders.	PHASE1/PHASE2	RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Quantification of GADD34 Expression in RA	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Effect of Protein on Endoplasmic Reticulum Stress	nan	NOT_YET_RECRUITING
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Efficacy and Safety of Administration of High Levels of Protein to Critically Ill Patients.	nan	ACTIVE_NOT_RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EIF2AK3 binder may also engage these)

Protein	Name	Similarity
A5D791	—	1.000	A5D791 →
Q9Z2B5	—	1.000	Q9Z2B5 →
Q9Z1Z1	—	0.998	Q9Z1Z1 →
Q6DFV7	—	0.989	Q6DFV7 →
Q9FY74	—	0.988	Q9FY74 →
Q640L3	—	0.988	Q640L3 →
Q9Z2R9	—	0.988	Q9Z2R9 →
Q9Z2U2	—	0.988	Q9Z2U2 →
Q92613	—	0.988	Q92613 →
Q3UMB5	—	0.987	Q3UMB5 →
Q8K4P8	—	0.987	Q8K4P8 →
P33279	—	0.987	P33279 →
Q7XIT1	—	0.987	Q7XIT1 →
Q9JKY3	—	0.987	Q9JKY3 →
GSAP	Gamma-secretase-activating protein	0.987	landscape →
P35054	—	0.987	P35054 →
Q76N89	—	0.987	Q76N89 →
Q62661	—	0.987	Q62661 →
Q13129	—	0.987	Q13129 →
Q8TEV9	—	0.987	Q8TEV9 →
Q6PUR7	—	0.987	Q6PUR7 →
Q9D684	—	0.986	Q9D684 →
E7FA21	—	0.986	E7FA21 →
Q640U0	—	0.986	Q640U0 →
Q60610	—	0.986	Q60610 →
Q4R8E0	—	0.986	Q4R8E0 →
Q9EQY0	—	0.986	Q9EQY0 →
Q9Z179	—	0.986	Q9Z179 →
Q3U3V8	—	0.986	Q3U3V8 →
Q1LUT1	—	0.986	Q1LUT1 →